Publications by authors named "Charline Kieffer"

Article Synopsis
  • XIAP is a protein that helps regulate cell survival and inflammation, and targeting it could benefit diseases like Crohn's disease and sarcoidosis.
  • Researchers developed selective inhibitors for a specific part of XIAP (XIAP-BIR2) to disrupt its interaction with RIPK2, which is relevant to inflammatory diseases.
  • They created a library of small synthetic molecules, identifying compound 20c, which effectively blocks the NOD1/2 signaling pathway in cells and holds potential as an anti-inflammatory treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Molecular Glue Degraders (MGDs) help two proteins work together better in our cells, acting like a bridge between them.
  • This technology is important because it could help target proteins that medicine usually can't reach, making it easier to develop new treatments.
  • By using different methods to design MGDs, researchers hope to find new ways to treat tough diseases like infections and brain disorders that don't respond well to regular medicines.
View Article and Find Full Text PDF
Article Synopsis
  • XIAP (X-linked inhibitor of apoptosis protein) inhibits caspases, which are essential for cell death, and its overexpression in cancers allows tumor cells to avoid apoptosis, making it a target for cancer therapy.
  • The study focuses on developing selective antagonists that inhibit XIAP's function without affecting cIAP1-2, as existing inhibitors cause undesirable side effects.
  • By using molecular dynamics simulations and pharmacophore modeling, the researchers identified crucial residues for binding and suggested three residues (Lys297, Thr308, Asp309) that could enhance the specificity of XIAP-BIR3 antagonists.
View Article and Find Full Text PDF
Article Synopsis
  • Target Protein Degradation (TPD) is a new way to develop medicines that changes how we think about drug discovery.
  • Since the first PROTAC was created in 2001, TPD has quickly grown and can help with both finding new drugs and understanding biology.
  • This work talks about the challenges faced in using PROTACs and shares new results to help scientists create better drugs.
View Article and Find Full Text PDF

Protein-protein interactions (PPIs) constitute many potential therapeutic targets for the discovery of new drugs. Given their specificity, PPIs are more challenging to target than other ligands. Thus, finding the best screening process can be difficult.

View Article and Find Full Text PDF

From 4 antiplasmodial hit-molecules identified in 2-trichloromethylquinazoline series, we conducted a global Structure-Activity relationship (SAR) study involving 26 compounds and covering 5 molecular regions (I - V), aiming at defining the corresponding pharmacophore and identifying new bioactive derivatives. Thus, after studying the aniline moiety in detail, thienopyrimidine, quinoline and quinoxaline bio-isosters were synthesized and tested on the K1 multi-resistant P. falciparum strain, along with a cytotoxicity evaluation on the human HepG2 cell line, to define selectivity indecies.

View Article and Find Full Text PDF

An antileishmanial pharmacomodulation at position 4 of 8-nitroquinolin-2(1H)-one was conducted by using the Sonogashira and Suzuki-Miyaura coupling reactions. A series of 25 derivatives was tested in vitro on the promastigote stage of Leishmania donovani along with an in vitro cytotoxicity evaluation on the human HepG2 cell line. Only the derivatives bearing a phenyl moiety at position 4 of the quinoline ring displayed interesting biologic profile, when the phenyl moiety was substituted at the para position by a Br or Cl atom, or by a CF3 group.

View Article and Find Full Text PDF

From a recently identified antileishmanial pharmacophore, a structure-activity relationship study was conducted by introducing various aminated, phenoxy or thiophenoxy moieties at position 4 of the 8-nitroquinolin-2(1H)-one scaffold, using SNAr reactions. Thus a series of 47 derivatives was synthesized and evaluated in vitro on the promastigote stage of Leishmania donovani. In parallel, the cytotoxicity of the active molecules was tested on the human HepG2 cell line.

View Article and Find Full Text PDF

Thanks to a preliminary in vitro screening of several CCl3-substituted-nitrogen containing heterocycles belonging to our chemical library, the 2-trichloromethylquinoxaline scaffold appeared to be of potential interest for developing new antiplasmodial agents. Then, combining these experimental results to the antimalarial properties reported for various pyrrolo[1,2-a]quinoxaline derivatives, an original series of fifteen 7-substituted-4-trichoromethylpyrrolo[1,2-a]quinoxalines was synthesized in a 4 to 5 reaction steps pathway. All molecules were evaluated in vitro toward both their antiplasmodial activity on the K1 multi-resistant Plasmodium falciparum strain and their cytotoxicity on the HepG2 human cell line.

View Article and Find Full Text PDF

We report herein a simple and efficient two-step synthetic approach to new 2-trichloromethylquinazolines possessing a variously substituted sulfonamide group at position 4 used to prepare new quinazolines with antiparasitic properties. Thus, an original series of 20 derivatives was synthesized, which proved to be less-toxic than previously synthesized hits on the human HepG2 cell line, but did not display significant antiplasmodial activity. A brief Structure-Activity Relationship (SAR) evaluation shows that a more restricted conformational freedom is probably necessary for providing antiplasmodial activity.

View Article and Find Full Text PDF